Kbi-110 Page

| Disease | Current Standard | Unmet Need | How KBI‑110 Could Help | |---------|------------------|------------|------------------------| | | Cytarabine‑based chemotherapy, venetoclax + azacitidine | High relapse rates, drug‑resistance driven by epigenetic plasticity | Targeted epigenetic brake that spares normal hematopoiesis; oral administration reduces hospital burden | | IPF | Nintedanib, pirfenidone (both with GI & hepatic toxicity) | Limited efficacy; progressive fibrosis despite therapy | Directly dampens BRD9‑driven fibrotic transcription; potential for combination with anti‑fibrotic agents | | ALS | Riluzole, edaravone (modest survival benefit) | No disease‑modifying therapy; neuroinflammation a key driver | Microglial BRD9 inhibition may curb chronic neuroinflammation without broad immunosuppression |

Iterative structure‑guided medicinal chemistry (leveraging co‑crystal structures of BRD9‑KBI‑001) led to a series of that improved both potency and metabolic stability. The fifth generation, bearing a pyridyl‑urea moiety and a tetrahydro‑isoquinoline side chain, emerged as KBI‑110 . Its key properties are summarized below: KBI-110

(Prepared: 11 April 2026)

The Keyboard Interrupt is a specialized hardware feature that allows the processor to detect a change on specific input pins (usually Port 0) and trigger an interrupt. This means your code doesn't have to constantly "poll" or check if a button was pressed, which saves a massive amount of CPU cycles and battery life. Why Page 110 is Your Best Friend | Disease | Current Standard | Unmet Need